I got not nothing new from this other than the dose will be decided in early 2024 (Jan/Feb).
Absolutely nothing on MPS deal/update. One can only think that a) they have no interest or b) they have a short-list and will finalise terms over the next few months as MPS VI data comes in.
I suspect that any upfronts for MPS will be quarantined to progress that asset. Would make sense to raise for KOA trials/expense when MPS deal announced.
IMO only.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-5
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.040(15.1%) |
Mkt cap ! $78.80M | |||
| Open | High | Low | Value | Volume |
| 26.5¢ | 26.5¢ | 22.0¢ | $503.0K | 2.101M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 210000 | 2 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |